Clinical Trial: Testing the Anti-cancer Drug DSP-5336 (Enzomenib) in Prostate Cancer

U.S., Nov. 5 -- ClinicalTrials.gov registry received information related to the study (NCT07914855) titled 'Testing the Anti-cancer Drug DSP-5336 (Enzomenib) in Prostate Cancer' on Oct. 31.

Brief Summary: This phase II trial tests how well enzomenib works in treating patients with prostate cancer that has spread from where it first started (primary site) to other places in the body (metastatic) and has continued to grow or spread despite androgen deprivation therapy (castration-resistant). The growth and survival of prostate tumor cells often depends on testosterone. Androgen deprivation therapy blocks the use of testosterone by the tumor cells. Although most tumors respond to androgen deprivation therapy at first, nearly all eventually pr...